CANCER DRUG DEVELOPMENT PIPELINE
Oncology Drug Pipeline & Cancer Clinical Trials
Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
PF-08046045 (35T) | New project
Advanced Solid Tumors and Lymphomas (Biologic)
CD-30 directed antibody-tripeptide MMAE conjugate
PF-08046049 (BB228) | New project
Advanced Melanoma and Other Solid Tumors (Biologic)
CD228-directed antibody-Anticalin bispecific protein
PADCEV (enfortumab vedotin) | New project
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)
Nectin-4 directed antibody-drug conjugate